Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued Access to Xolair for Severe Allergic Asthma
NCT00109200Phase 3Completed
- Sponsor
- Genentech
- Start
- May 2003
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of omalizumab in asthma, sponsored by Genentech. Started May 2003; status: completed.
02
Drugs
omalizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00109200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109200.